Corey Hopkins
-
Collaboration seeks to develop new therapies for bone, other diseases
La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders. Read MoreOct 1, 2015
-
Growth factor blockade targets breast tumors
Inhibition of BMP growth factor signaling reduces breast tumor burden and metastasis. Read MoreAug 14, 2014
-
Small molecule protects kidney filter
A compound identified at Vanderbilt has therapeutic potential in protecting the kidney filter barrier. Read MoreMar 19, 2014
-
VU researcher has personal motive for investigating malaria
Vanderbilt researcher and Gabon, Africa, native is working to discover ways to kill malaria-spreading mosquitoes. Read MoreFeb 3, 2012
-
Drug-like molecules aimed at improving treatment of Parkinson’s
Drug-like molecules described by Vanderbilt researchers could lead to Parkinson's treatments with fewer side effects. Read MoreSep 30, 2011